Skip to main content
Top
Published in: Familial Cancer 2/2021

01-04-2021 | Pancreatic Cancer | Short Communication

Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants

Authors: Robert Power, Cristin Leavy, Carmel Nolan, Niamh White, Roisin Clarke, Karen A. Cadoo, David James Gallagher, Maeve Aine Lowery

Published in: Familial Cancer | Issue 2/2021

Login to get access

Abstract

Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are associated with an increased lifetime risk of pancreatic ductal adenocarcinoma (PDAC), and more recently have been associated with increased risk of biliary tract cancers (BTC). This study assessed the prevalence, age and gender distribution of PDAC/BTC cases in families known to carry a BRCA1/2 PV compared to those of the Irish population. A review of all families referred to a national genetics clinic from 09/11/1997 to 01/06/2018 was performed. The BOADICEA algorithm was used to estimate the probability that an untested relative of a known BRCA1/2 PV carrier with PDAC was a carrier. We reviewed 3252 family pedigrees, 1193 contained a proband who underwent testing for BRCA1/2 based on Manchester score ≥ 15. Among 128 BRCA2 PV-positive families, 27 (21%) contained a 1st/2nd/3rd-degree relative with PDAC, while of 116 BRCA1 PV-positive families, 11 (9%) contained a 1st/2nd/3rd-degree relative with PDAC. Within these 38 families, 25 patients with PDAC had ≥ 50% likelihood of being a BRCA1/2 PV carrier. This cohort had a median age at diagnosis of 55 years (range 33–75), with a mean (55 years) lower than 8364 patients with PDAC identified through the National Cancer Registry of Ireland (71 years, p < 0.0001). Six BRCA2 positive (5%) and 2 BRCA1 positive pedigrees (2%) included an individual with BTC; median age at diagnosis was 65 years (range 33–99). PDAC and BTC are prevalent in Irish families harbouring a BRCA2 PV and are associated with early-onset malignancy. This supports current guidelines recommending universal germline testing for PDAC patients.
Literature
1.
go back to reference NCRI (2019) Cancer in Ireland 1994–2017 with estimates for 2017–2019: annual report of the National Cancer Registry. NCRI, Cork NCRI (2019) Cancer in Ireland 1994–2017 with estimates for 2017–2019: annual report of the National Cancer Registry. NCRI, Cork
Metadata
Title
Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants
Authors
Robert Power
Cristin Leavy
Carmel Nolan
Niamh White
Roisin Clarke
Karen A. Cadoo
David James Gallagher
Maeve Aine Lowery
Publication date
01-04-2021
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2021
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00205-1

Other articles of this Issue 2/2021

Familial Cancer 2/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine